Geovax Labs Stock (NASDAQ:GOVX), Trade Ideas

Geovax Labs

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

BENF

GOVX

The Dow Jones index closed higher by over 450 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying

CATX

VRME

The Dow Jones index closed higher by over 150 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

GeoVax Labs And 2 Other Stocks Under $2 Insiders Are Buying

ASPU

FBIO

RCAT

The Dow Jones closed lower by around 69 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

GeoVax Labs And 3 Other Stocks Under $1 Insiders Are Buying

Geovax Labs Inc

<a href="https://twitter.com/DrTedros/status/1778423967105139108">https://twitter.com/DrTedros/status/1778423967105139108</a>
&nbsp;
&nbsp;

Biotech

Global

General

AEMD

CMRX

MRNA

SIGA

TNXP

WHO's Tedros Adhanom Ghebreyesus Posts On X "In #DRC alone, more than 4500 cases of #mpox and almost 300 deaths have been reported this year. That is triple the number reported at this time last year. The recent surge in cases and deaths among children is of particular concern, along with the re-emergence of Clade One in central Africa...."

<h3>Gainers</h3>
<ul>
<li>Protara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million. </li>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares moved upwards by 25.93% to $8.06. The company's market cap stands at $236.5 million. </li>
<li>Etao International Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETAO#NASDAQ">ETAO</a>) shares moved upwards by 25.61% to $3.58. The market value of their outstanding shares is at $18.3 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares rose 11.11% to $2.5. The company's market cap stands at $21.3 million. </li>
<li>scPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>) stock moved upwards by 10.7% to $5.69. The company's market cap stands at $205.1 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares moved upwards by 8.33% to $1.95. The company's market cap stands at $12.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) stock decreased by 17.8% to $0.42 during Friday's pre-market session. The market value of their outstanding shares is at $20.0 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares declined by 8.72% to $1.78. The company's market cap stands at $4.3 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) stock fell 8.64% to $1.27. The company's market cap stands at $11.9 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock fell 8.46% to $5.63. The company's market cap stands at $4.9 million. </li>
<li>MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) shares decreased by 8.21% to $1.23. The market value of their outstanding shares is at $42.6 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) stock decreased by 7.94% to $1.85. The market value of their outstanding shares is at $4.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CADL

ETAO

HSDT

IMNN

INDP

INKT

MTEM

SCPH

TARA

TCBP

12 Health Care Stocks Moving In Friday's Pre-Market Session

GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company's next-generation Covid-19 vaccine candidate, during the upcoming 24th Annual World Vaccine Congress taking place in Washington, DC on April 1-4, 2024. &nbsp;
Presentation Details: Presenter:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Mark Newman, PhD, Chief Scientific Officer Date/Time:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Thursday, April 4, 2024, 12:00 pm ET Location:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Walter E. Washington Convention Center, Washington, DC Presentation Title: Vaccine Induction of Broadly-Specific Antibody and T Cell Responses to Combat SARS-CoV-2 Variation
Dr. Newman's presentation will focus on results delineating the unique immune system driven mechanisms that contribute to the broad efficacy of GeoVax's next-generation Covid-19 vaccine, GEO-CM04S1.
About GEO-CM04S1
GEO-CM04S1 is based on GeoVax's MVA viral vector platform, which supports the presentation of multiple vaccine antigens to the immune system in a single dose. GEO-CM04S1 encodes for both the spike (S) and nucleocapsid (N) antigens of SARS-CoV-2 and is specifically designed to induce both antibody and T cell responses to those parts of the virus less likely to mutate over time. The more broadly functional engagement of the immune system is designed to protect against severe disease caused by continually emerging variants of Covid-19. Vaccines of this format should not require frequent and repeated modification or updating.
GEO-CM04S1 is currently being evaluated in three ongoing Phase 2 clinical trials:
<ul>
<li>As a primary vaccine in immunocompromised patients (with hematologic cancers receiving cell transplants or CAR-T therapy). ClinicalTrials.gov Identifier: <a href="https://www.clinicaltrials.gov/ct2/show/NCT04977024?term=COH04S1&amp;draw=2&amp;rank=1">NCT04977024</a>. A recent presentation of unpublished data from the open-label portion of the trial indicates that GEO-CM04S1 is highly immunogenic in these patients, inducing both antibody responses, including neutralizing antibodies, and T cell responses.</li>
<li>As a booster vaccine in immunocompromised patients with chronic lymphocytic leukemia (CLL), a recognized high-risk group for whom current mRNA vaccines and monoclonal antibody (MAb) therapies appear inadequate relative to providing protective immunity. ClinicalTrials.gov Identifier: <a href="https://classic.clinicaltrials.gov/ct2/show/NCT05672355">NCT05672355</a>.
<ul>
<li>As a booster vaccine for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine. This trial was fully enrolled in September 2023 and final results are expected in Fourth Quarter 2024, reflecting a 12-month tracking of study patients. ClinicalTrials.gov Identifier: <a href="https://www.clinicaltrials.gov/ct2/show/NCT04639466?term=COH04S1&amp;draw=2&amp;rank=2">NCT04639466</a>.</li>
</ul>
</li>
</ul>

GeoVax To Present Data On GEO-CM04S1, A Next Generation Covid-19 Vaccine, At The World Vaccine Congress

Offerings

GeoVax Labs Inc Files For Mixed Shelf Of Up To $100M

Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) reported its Q4 earnings results on Thursday, February 29, 2024 at 04:00 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Geovax Labs missed estimated earnings by -42.0%, reporting an EPS of $-3.94 versus an estimate of $-2.78.
Revenue was down $0 from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $1.2 which was followed by a 2.0% drop in the share price the next day.

To track all earnings releases for Geovax Labs <a href="https://www.benzinga.com/quote/GOVX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Geovax Labs: Q4 Earnings Insights

Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) reported quarterly losses of $(3.940) per share which missed the analyst consensus estimate of $(2.780) by 41.73 percent.

Earnings Misses

Geovax Labs Q4 2023 GAAP EPS $(3.940) Misses $(2.780) Estimate

ABUS

ACIC

ACIW

ADSK

AINC

AKLI

AMRN

AMWD

ANIP

ARGX

ARLO

AVPT

BBWI

BIRK

BLFS

BRFH

CAPR

CCOI

CDRO

CELH

CERT

CMPS

COMM

CPSI

CRAI

CRDF

CRON

CUBE

CVEO

DAVA

DELL

DHIL

DMTK

DOLE

DOUG

ESAB

ESTC

EVLV

EVRG

EVRI

EXLS

FDUS

FIHL

FREY

FSCO

GDEN

GDRX

GECC

GLNG

GOLF

GRBK

HAYW

HYFM

IHRT

INSW

INUV

ITRN

JAKK

KPTI

LSEA

LSTA

Melco Resorts & Entertainment Limited - American Depositary Shares

MLCO

MNTX

MPLN

NBBK

Earnings Scheduled For February 29, 2024

Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) is set to give its latest quarterly earnings report on Thursday, 2024-02-29. Here's what investors need to know before the announcement.
Analysts estimate that Geovax Labs will report an earnings per share (EPS) of $-2.78. 
Geovax Labs bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $1.20, which was followed by a 1.65% drop in the share price the next day.
Here's a look at Geovax Labs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-3.6</td>
<td>-2.4</td>
<td>-3</td>
<td>-3</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-4.8</td>
<td>-3.3</td>
<td>-2.25</td>
<td>-3</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709146930_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Geovax Labs were trading at $2.71 as of February 27. Over the last 52-week period, shares are down 76.12%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/GOVX/earnings">To track all earnings releases for Geovax Labs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Geovax Labs

The Dow Jones index closed higher by over 450 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>GeoVax Labs </h3>
<ul>
<li>The Trade: GeoVax Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/govx#NASDAQ">GOVX</a>) President, CEO David A Dodd <a href="https://www.benzinga.com/quote/GOVX/analyst-ratings"> acquired a total of 8,729 shares </a> an average price of $2.27. To acquire these shares, it cost around $19,781.</li>
<li>What&rsquo;s Happening: GeoVax is expected to report 2023 financial results on Feb. 29, 2024.</li>
<li>What GeoVax Labs Does: Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms.</li>
</ul>
<h3>Beneficient</h3>
<ul>
<li>The Trade: Beneficient (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/benf#NASDAQ">BENF</a>) Director Peter T Cangany Jr <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 400,000 shares at </a> at an average price of $0.26. To acquire these shares, it cost around $102,000.</li>
<li>What&rsquo;s Happening: On Feb. 13, Beneficient posted a wider quarterly loss.</li>
<li>What Beneficient Does: Beneficient is a technology-enabled financial services holding company that (together with its subsidiaries) provides simple, rapid, and cost-effective liquidity solutions to participants in the alternative asset industry through its end-to-end online platform, AltAccess.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/02/37279661/warner-bros-discovery-block-and-3-stocks-to-watch-heading-into-friday"> Warner Bros. Discovery, Block And 3 Stocks To Watch Heading Into Friday </a>
<h3>InMed Pharmaceuticals </h3>
<ul>
<li>The Trade: InMed Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inm#NASDAQ">INM</a>) Director Andrew Hull <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 37,500 shares </a> at an average price of $0.39. The insider spent around $14,625 to buy those shares.</li>
<li>What&rsquo;s Happening: InMed Pharmaceuticals, on Oct. 24, said it selected a lead Alzheimer&#39;s drug candidate following positive proof-of-concept study data.</li>
<li>What InMed Pharmaceuticals Does: InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company.</li>
</ul>

Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Geovax Labs On Feb 16, Received Letter From Nasdaq Stating Co To Have Regained Compliance With Nasdaq Listing Requirements

Intellectual Property Assets Strengthened for Cancer Immunotherapy Program and for Marburg Virus and HIV Vaccines
ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via <a href="https://www.globenewswire.com/Tracker?data=GFQr7TOp-9JketoL9GFtAv1hnMisZj_efmnZcZ98klDlYKIFoHiZFeD-ptRDkA1OqdVO_s63RTFLQZlVpcvjldOdrg-Oeu54dxMTvZ-bZYE=">NewMediaWire</a> – GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced multiple actions by global patent offices strengthening the Company's intellectual property assets.
<ul>
<li>The Japanese Patent Office issued a Decision of Grant notifying GeoVax of the allowance of the Company's Patent Application No. 2022-153352 titled "Compositions and Methods for Generating an Immune Response to a Tumor Associated Antigen." The allowed claims are directed to recombinant MVA viral vectors comprising specific MUC-1 nucleic sequences used in GeoVax's MUC-1 tumor-associated antigen immunotherapy program. Pharmaceutical compositions for inducing immune responses, preventing or reducing neoplasm growth, or treating cancer are also covered by the granted claims.</li>
<li>The U.S. Patent and Trademark Office issued Patent No. 11,896,657 to GeoVax, pursuant to the Company's patent application No. 17/584,231 titled "Replication-Deficient Modified Vaccinia Ankara (MVA) Expressing Marburg Virus Glycoprotein (GP) and Matrix Protein (VP40)." The allowed claims generally cover GeoVax's vector platform for expressing Marburg virus antigens in virus-like particles (VLPs) utilizing an MVA viral vector.</li>
<li>The U.S. Patent and Trademark Office issued Patent No. 11,897,919 pursuant to the Company's patent application No. 17/409,574 titled "Multivalent HIV Vaccine Boost Compositions and Methods of Use." The allowed claims generally cover a priming vaccination with a DNA vector encoding multiple HIV antigens in virus-like particles (VLPs), followed by a boost vaccination with GeoVax's vector platform for expressing HIV-1 antigens in VLPs utilizing an MVA viral vector.</li>
</ul>
David Dodd, GeoVax President and CEO, commented, "These patent actions add to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, now standing at over 115 granted or pending patent applications spread over 24 patent families. Our development priorities continue to be our next-generation Covid-19 vaccine, currently in Phase 2 clinical trials, and our cancer immunotherapy program, with Gedeptin&#xAE; as our lead product in a Phase 1/2 clinical trial for advanced head and neck cancer. Beyond these two programs, we continue to investigate MVA as a cancer immunotherapy platform, as it has shown interesting potential to address multiple cancer indications."
Mr. Dodd continued, "Although not currently under active development, our HIV program forms an important part of the dataset underpinning all of our MVA-based development programs. The patent protection associated with this vaccine is an important part of this technology platform. Also, our team is committed to supporting the successful advancement of vaccines against lethal hemorrhagic fever viruses such as Marburg virus, as we recognize the critically important medical and biodefense need, reflected by the inclusion of Marburg virus in the FDA Priority Review Voucher program."

GeoVax Announces Multiple Actions By Global Patent Offices Strengthening The Company's Intellectual Property Assets; Intellectual Property Assets Strengthened For Cancer Immunotherapy Program And For Marburg Virus And HIV Vaccines

<ul>
<li>Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants</li>
</ul>

GeoVax Reports Interim Data From Phase 2 Clinical Trial Of GEO-CM04S1 As Universal Covid-19 Vaccine Booster

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Stock Split

GeoVax Announces 1-for-15 Reverse Stock Split To Regain Compliance With Nasdaq Minimum Bid Requirement

<h3>Gainers</h3>
<ul>
<li>Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) stock rose 39.6% to $18.73 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) stock moved upwards by 24.51% to $1.11. The company's market cap stands at $21.8 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock increased by 17.33% to $0.44. The market value of their outstanding shares is at $2.4 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares moved upwards by 14.76% to $0.65. The company's market cap stands at $4.0 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares moved upwards by 13.97% to $1.06. The market value of their outstanding shares is at $50.8 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares increased by 12.42% to $0.26. The market value of their outstanding shares is at $6.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock decreased by 16.5% to $2.02 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.7 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares decreased by 6.84% to $8.72. The company's market cap stands at $17.7 million. </li>
<li>Pluri (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUR#NASDAQ">PLUR</a>) shares fell 6.79% to $0.62. The market value of their outstanding shares is at $25.5 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock declined by 6.44% to $0.16. The company's market cap stands at $2.1 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) stock decreased by 6.1% to $0.26. The company's market cap stands at $56.7 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) stock declined by 5.77% to $0.26. The company's market cap stands at $7.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

BIVI

CELU

CNSP

KURA

PLUR

RDHL

SBFM

SNOA

VTVT

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

GeoVax Announces Gedeptin Patient Enrollment Closure For Phase 1/2 Clinical Trial Among Advanced Head And Neck Cancer Patients

Patent Covers Multiple Component Vaccine for Both Prevention and Treatment &nbsp;
ATLANTA, GA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- via <a href="https://www.globenewswire.com/Tracker?data=_9yk_3snz7DPW94bCtJnxwAzy1s61q9_Sq78pdj30M_VV0ey2UHkuiLc6xMY-mdwb19mdu0QVZMs_0fdwDotIoA87PBCw0PToRMu5Hl9Llk=">NewMediaWire</a> –&nbsp;GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases,&nbsp;today&nbsp;announced that the U.S. Patent and Trademark Office has issued Patent No. 11,857,611 to GeoVax, pursuant to the Company's patent application No. 17/726,254 titled "Compositions and Methods for Generating an Immune Response to Treat or Prevent Malaria."
The claims granted by the patent generally cover compositions comprising GeoVax's modified vaccinia Ankara (MVA) vector expressing Plasmodium antigens and methods of inducing an immune response to malaria utilizing the compositions. The compositions and methods covered in the claims are useful both prophylactically and therapeutically and may be used to prevent and/or treat malaria.
David Dodd, GeoVax President and CEO, commented, "During 2023, there were the first cases of locally transmitted malaria reported in the United States in 20 years, with cases reported in Florida, Maryland and Texas. Worldwide, there are over 600,000 deaths annually attributed to malaria. This patent represents a potentially significant advance against a most critical deadly threat worldwide. While our focus and priority is to support our clinical-stage programs, we also remain strongly committed to improving public health worldwide and developing vaccines against global public health threats, such as malaria, as a part of our long-term vision for the company."
According to data from the World Health Organization, globally, malaria causes 227 million infections and 619,000 deaths annually. Despite decades of vaccine research, vaccine candidates have failed to induce substantial protection. Most of these vaccines are based on individual proteins that induce immune responses targeting only one stage of the malaria parasite's life cycle. GeoVax's MVA-VLP malaria vaccine candidates incorporate antigens derived from multiple stages of the parasite's life cycle and are designed to induce an immune response with durable functional antibodies and CD4+ and CD8+ T cell responses, all hallmarks of an ideal vaccine-induced immune response.

GeoVax Announces Issuance of Malaria Vaccine Patent, Patent Covers Multiple Component Vaccine For Both Prevention And Treatment

The Dow Jones index closed higher by over 150 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Perspective Therapeutics</h3>
<ul>
<li>The Trade: Perspective Therapeutics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/catx#NYSE">CATX</a>) Director Robert F. Williamson III<a href="https://www.benzinga.com/quote/CATX/analyst-ratings"> acquired a total of 3,663 shares</a> an average price of $0.33. To acquire these shares, it cost around $1,203.</li>
<li>What&rsquo;s Happening: Perspective Therapeutics recently announced it agreed to fully divest its brachytherapy business.</li>
<li>What Perspective Therapeutics Does: Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body.</li>
</ul>
<h3>VerifyMe</h3>
<ul>
<li>The Trade: VerifyMe, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrme#NASDAQ">VRME</a>) CEO Adam Stedham <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 1,953 shares </a> at an average price of $1.04. To acquire these shares, it cost around $2,031.</li>
<li>What&rsquo;s Happening: VerifyMe board approved a share repurchase program of up to $500,000.</li>
<li>What VerifyMe Does: VerifyMe Inc is a technology solutions company based in the United States. It markets a broad patent portfolio that includes patents in the field of authenticating products, people, and financial transactions.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/12/36380862/how-to-earn-500-a-month-from-nike-stock-following-quarterly-report"> How To Earn $500 A Month From Nike Stock Following Quarterly Report </a>
<h3>GeoVax Labs </h3>
<ul>
<li>The Trade: GeoVax Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/govx#NASDAQ">GOVX</a>) Chief Medical Officer Kelly McKee <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 6,944 shares </a> at an average price of $0.36. The insider spent around $2,500 to buy those shares.</li>
<li>What&rsquo;s Happening: GeoVax expanded rights under NIH COVID-19 license to include Mpox and smallpox.</li>
<li>What GeoVax Labs Does: Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms.</li>
</ul>
&nbsp;
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
&nbsp;

GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has amended a previously executed Patent and Biological Materials License Agreement (the "License Agreement") with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), in support of GeoVax's development of a vaccine against SARS-CoV-2 (COVID-19). The amendment expands GeoVax's commercial license to include Mpox and smallpox as additional indications.
The License Agreement, as amended, allows GeoVax to use these materials and patent rights owned by agencies of the United States Department of Health and Human Services (HHS) in combination with the Company's proprietary technology for the creation of preventive Modified Vaccinia Ankara Virus-Virus Like Particle (MVA-VLP) vaccines that prime and/or boost the immune system against SARS-CoV-2 (the virus that causes COVID-19) as well as Mpox and/or smallpox. Financial terms of the License Agreement were not disclosed.

Contracts

GeoVax Expands Rights Under NIH COVID-19 License To Include Mpox And Smallpox; Financial Terms Of The License Agreement Were Not Disclosed

GeoVax Labs to effect 1-for-15 reverse stock split to regain compliance with Nasdaq rule

Geovax Labs Inc (GOVX) stock is down -73.07% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives GOVX stock a score of  26 out of a possible 100. That rank is chiefly influenced by a long-term technical score of 2. GOVX's rank also

Should You Buy Geovax Labs Inc (GOVX) Stock Thursday?

These Healthcare stocks are trading higher:-4D Molecular Therapeutics Inc (FDMT) stock is trading at $31.73, a gain of $14.24, or 81.32%, on high volume.  4D Molecular Therapeutics Inc gets a Sentiment Score of Very Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price tar

Healthcare Stocks Making Moves Monday: FDMT, MOR, ADVM, KPTI, INBS, UPC, AHG, GOVX

GeoVax Labs (GOVX) has released an update. A company facing delisting from the Nasdaq Capital Market due to its stock price falling below the minim...

GeoVax Labs Avoids Nasdaq Delisting with Reverse Stock Split

The market has been high on Geovax Labs Inc (GOVX)  stock recently. GOVX gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Geovax Labs Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on GOVX!See Full GOVX ReportWhat is Stock Sentiment?In investing,

Where Will Geovax Labs Inc (GOVX) Stock Go Next After It Has Gained 9.75% in a Week?

GeoVax GAAP EPS of -$14.29 beats by $0.26

GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GeoVax Labs (GOVX – Research Report), Madrigal Pha...

Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX), Madrigal Pharmaceuticals (MDGL) and Spyre Therapeutics (SYRE)

GeoVax Labs files $100M mixed securities shelf

In a report released today, Robert LeBoyer from Noble Financial maintained a Buy rating on GeoVax Labs (GOVX – Research Report), with a price targe...

Noble Financial Reaffirms Their Buy Rating on GeoVax Labs (GOVX)

ADVM

FDMT

GOVXW

INBS

MDGL

SYRE

Press Releases

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

Legal

GeoVax Announces Multiple Patent Issuances and Allowances

GeoVax to Present at the 2024 BIO CEO & Investor Conference

GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

GeoVax to Present at the 36th Annual Roth Conference

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress